Introduction
============

Colorectal cancer (CRC) is a widespread carcinoma and has more than 600,000 associated mortalities annually worldwide.[@b1-ott-10-4739],[@b2-ott-10-4739] CRC is one of the most common cancers of the gastrointestinal tract. After lung and breast cancers, CRC ranks third among the most common cancers worldwide.[@b3-ott-10-4739],[@b4-ott-10-4739] Colon cancer mortality ranks fourth among cancer-related mortalities. CRC incidence and mortality increase with age. In China, the incidence of CRC has been rising because of improved living standards and the shift to high-protein, high-calorie, and low-fiber diet. According to the cancer statistics in 2016, the incidence of CRC in China was 33.1 million, which ranked fourth in all malignant tumors. The mortality of CRC in China was 15.9 million, which ranked fifth in cancer deaths.[@b5-ott-10-4739] Colon cancer mortality increased by 15.22% in China, among which female colon cancer mortality ranked third among malignant carcinomas, whereas that of males ranked fourth.[@b6-ott-10-4739] Paired boxed gene 1 (*PAX1*) and sex-determining region Y-related high-mobility group box 1 (*SOX1*) are tumor suppressor genes. Previous studies demonstrated that *PAX1* was silenced because of hypermethylated status in many carcinomas, especially in cervical, ovarian, and oral cancers.[@b7-ott-10-4739]--[@b10-ott-10-4739] *PAX1* methylation is a potential biomarker to screen cervical cancer, as well as oral squamous cell carcinoma, with high sensitivity and specificity.[@b8-ott-10-4739],[@b11-ott-10-4739],[@b12-ott-10-4739] *SOX1* is a tumor suppressor that was suppressed by the hypermethylation of its promoter region in various carcinomas, including cervical, hepatocellular, and nasopharyngeal cancers.[@b10-ott-10-4739],[@b12-ott-10-4739],[@b13-ott-10-4739] However, the methylation of *PAX1* or *SOX1* in CRC has not been analyzed yet.

CRC and other carcinomas are often caused by an accumulation of genetic and epigenetic alterations, among which DNA methylation is the most frequent epigenetic alteration. DNA methylation usually occurs at carbon 5 of the cytosine ring within the CpG dinucleotides, and this process is a major epigenetic modification in the human genome.[@b14-ott-10-4739]--[@b16-ott-10-4739] DNA hypermethylation is an important mechanism to inactivate tumor suppressor genes that could be involved in DNA repair, metabolism of cancer, cell cycle control, apoptosis, and angiogenesis.[@b15-ott-10-4739],[@b17-ott-10-4739],[@b18-ott-10-4739] However, a few hypermethylated genes have been associated with CRC, and a limited number of studies have focused on prognostic methylation biomarker in CRC. To the best of our knowledge, *APC*, *RASSF1A*, *FAS*, *ZNF582*, *GFRA1*, and *GSTM2* promoter hypermethylation has been reported to be involved in the development with CRC.[@b19-ott-10-4739]--[@b22-ott-10-4739] However, whether the promoter methylation status of the *PAX1* and *SOX1* genes is associated with CRC remains to be elucidated.

In this study, the methylation status of *PAX1* and *SOX1* in CRC tissues and paired paracarcinoma tissues was investigated using quantitative methylation-specific polymerase chain reaction (qMSP). The results were verified using data-sets from The Cancer Genome Atlas (TCGA) database.

Materials and methods
=====================

Patients and samples
--------------------

Samples of CRC tissues and adjacent normal tissues were collected from 41 patients with CRC. Written informed consents were signed by all patients before collection of specimens. This study was approved by the Institutional Review Board of Department of Clinical Pharmacology, Xiangya Hospital, Central South University (registration number: CTXY-1,50,001--2) and the Chinese Clinical Trial Registry (registration number: ChiCTR-DCD-1,50,06,289). Tumor tissues were defined as the sections next to the tumor diagnosed by histopathology. Paracancerous tissues were taken from surgically dissected tissues \~2 cm away from the defined tumor area without tumor invasion. The dissected tumor and paracancerous tissues were further evaluated histologically.

Genomic DNA was extracted from the tissues with the iSat Nucleic Acid Extraction kit (iStat Biomedical Co., Ltd., New Taipei City, Taiwan) according to the manufacturer's manual. The concentration of DNA was determined using BioSpec-Nano spectrophotometer (Shimadzu Company, Kyoto, Japan). Samples with a DNA yield of more than 500 ng were considered for further testing. Total RNA was extracted using TRIZOL reagent (Invitrogen, San Diego, CA, USA) according to the manufacturer's protocol and dissolved in 30 μL of diethylpyrocarbonate-treated water.

Determination of DNA methylation
--------------------------------

Sodium bisulfite conversion of 500 ng of genomic DNA was performed using the iStat Bisulfite Conversion Kit (iStat Biomedical Co., Ltd) according to the manufacturer's manual. The bisulfited DNA was stored at −80°C until used. The DNA methylation of *PAX1* and *SOX1* genes was analyzed using *PAX1* and *SOX1* DNA Detection Kits (iSat Biomedical Co., Ltd), which use simplified technology based on TaqMan technologies for qMSP. The qMSP reaction was conducted in a total volume of 20 μL containing 2 μL of bisulfite-converted template gDNA (50 ng), 1 μL of 2× custom detection mix, and 10 μL of 2× custom universal polymerase chain reaction (PCR) master mix. The reaction was performed using the LightCycler 480 Real-Time PCR System (Roche Applied Science, Penzberg, Germany) under the following conditions. The reaction systems were first subjected to an initial incubation at 95°C for 10 min, followed by 50 cycles at 95°C for 10 s, and annealing and extension at 60°C for 40 s. DNA methylation levels were assessed as the methylation index (meth-index) was calculated as follows: 10,000×2^(*Cp*\ value\ of\ gene-Cp\ value\ of\ *COL2A*)^. Testing results with *Cp* values of *COL2A* \>36 were defined as detection failures.

Quantitative reverse transcription-PCR
--------------------------------------

Single-stranded cDNA was prepared using a PrimeScript RT Reagent Kit (Takara, Otsu, Japan) according to the manufacturer's protocol. Quantitative reverse transcription-PCR (qRT-PCR) was performed using LightCycler 480 Real-Time PCR System (Roche Applied Science) by SYBR Premix DimerErase™ kit (Takara) to detect the expression of *SOX1* and *PAX1*, with *PPIA* and *B2M* as normalizing controls. The sequences of the primers used were as follows: *SOX1*: forward, 5′-CAGTACAGCCCCATCTCCAAC-3′ and reverse, 5′-GCGGGCAAGTACATGCTGA-3′; *PAX1*: forward, 5′-TCGCTATGGAGCAGACG TATG-3′ and reverse, 5′-GCTGCCGACTGATGTCACA-3′; *PPIA*: forward, 5′-CC CACCGTGTTCTTCGACATT-3′ and reverse, 5′-GGACCCGTATGCTTTAGGATGA-3′; and *B2M*: forward, 5′-GAGGCTATCCAGCGTACTCCA-3′ and reverse, 5′-CG GCAGGCATACTCATCTTTT-3′. The qRT-PCR reaction systems were performed with incubation at 95°C for 10 min, followed by 45 cycles at 95°C for 10 s, and annealing and extension at 60°C for 60 s. Relative quantification results were determined by 2^−ΔΔCt^ relative to the normalizing control genes.

Validation using TCGA data
--------------------------

The dataset of DNA methylation was obtained from the TCGA database, which included clinical information from 166 CRC tissues and 37 normal tissues. Level 3 datasets were obtained through Infinium HumanMethylation 27 BeadChip and analyzed using R software (<http://www.R-project.org/>).

Statistical analysis
--------------------

Paired-sampled *t*-test was performed to compare the methylation levels between the CRC and normal tissue samples. Correlations between the frequency of DNA methylation occurrence and clinicopathological characteristics of CRC patients were analyzed by *χ*^2^ test. Associations between DNA methylation status and clinicopathological characteristics of CRC patients were analyzed by Mann--Whitney *U*-test. Wilcoxon signed-rank test was performed to compare the methylation levels between CRC and paired normal tissues. *P*-values \<0.05 were considered statistically significant. Kaplan--Meier method was performed to evaluate the overall survival rates. Log-rank test was used to calculate the difference in survival. The association between methylation levels and relative mRNA expression was analyzed by calculating Pearson's correlation coefficient and *P*-values. All statistical analyses were performed using SPSS Statistics 19.0 software (IBM Corporation, Armonk, NY, USA).

Results
=======

Analysis of DNA methylation of *PAX1*/*SOX1* in CRC and paracancer tissues
--------------------------------------------------------------------------

DNA methylation status of *PAX1*/*SOX1* in 166 CRC patients was analyzed using TCGA datasets. [Figure 1A](#f1-ott-10-4739){ref-type="fig"} shows that the methylation levels of *PAX1* and *SOX1* genes were significantly greater in the 166 CRC samples than in the 37 normal samples (both *P*\<0.05). In addition, the methylation levels of the two genes were higher in the majority of the CRC samples than in their paired normal samples ([Figure 1B](#f1-ott-10-4739){ref-type="fig"}). The areas under the curve (AUCs) of the receiver-operating characteristic (ROC) plots for the methylation of *SOX1* and *PAX1* in 166 CRC and 37 normal tissues were 0.515 and 0.805, respectively ([Figure 1C](#f1-ott-10-4739){ref-type="fig"}). *SOX1* methylation testing achieved 78.3% sensitivity and 83.8% specificity, and *PAX1* methylation testing achieved 31.9% sensitivity and 100% specificity.

The results from the TCGA datasets were verified by detecting the methylation levels of *PAX1* and *SOX1* in the tissues of patients with CRC. A total of 41 patients with CRC were recruited from Xiangya Hospital in Changsha, China, between May 2015 and June 2016. Patient ages ranged from 24 to 84 years (median age, 57 years). The clinicopathological characteristics of these patients are presented in [Tables 1](#t1-ott-10-4739){ref-type="table"} and [4](#t4-ott-10-4739){ref-type="table"}. The CRC tissues showed a significantly greater level of hypermethylated *SOX1*/*PAX1* compared with their paired normal tissues as detected by qMSP (both *P*\<0.05, [Figure 2A and B](#f2-ott-10-4739){ref-type="fig"}). The methylation status of samples and frequencies were determined based on the best meth-index cut-off values calculated using the ROC curves ([Figure 2C and D](#f2-ott-10-4739){ref-type="fig"}). Log (meth-index) ≥3.6 for *SOX1* or log (meth-index) ≥3.7 for *PAX1* were considered to be methylation positivity. *PAX1* and *SOX1* genes were both methylated in 28 (68.3%) of the 41 CRCs samples but in 5 (12.2%) and 0 (0%) of paired normal control samples (both *P*\<0.001), respectively. The AUCs of the ROC plots in [Figure 2C and D](#f2-ott-10-4739){ref-type="fig"} for the methylation of *PAX1* and *SOX1* to detect CRC from normal tissues were 0.743 (95% CI 0.627--0.858) and 0.798 (95% CI 0.689--0.907), respectively ([Table 2](#t2-ott-10-4739){ref-type="table"}). At meth-index of 1.56, *PAX1* methylation testing achieved 68.3% sensitivity and 87.8% specificity. At meth-index of 3.01, *SOX1* methylation testing achieved 68.3% sensitivity and 100% specificity.

Furthermore, the correlation between the methylation status of *SOX1* and *PAX1* in the same CRC samples is analyzed in [Figure S1](#SD1-ott-10-4739){ref-type="supplementary-material"}. Pearson's correlation analysis showed that there is no linear relationship between the methylation status of *PAX1* and *SOX1* in the same CRC samples.

*PAX1*/*SOX1* methylation status and survival in CRC patients using TCGA datasets
---------------------------------------------------------------------------------

We used the TCGA dataset to investigate whether the methylation status of *SOX1* or *PAX1* influenced prognosis. The results from the Kaplan--Meier analysis illustrated no significant difference in the overall survival between patients with high and low methylation levels of *SOX1* or *PAX1* (*P*\>0.5, [Figure 1D](#f1-ott-10-4739){ref-type="fig"}). The mean survival time ± standard error (SE) of patients with CRC and low methylation level of *SOX1* was 619.0±42.2 days, while that of patients with CRC and high methylation level of *SOX1* was 602.2±49.8 days. The mean survival time ± SE of patients with CRC and low methylation level of *PAX1* was 603.4±44.9 days, while that of patients with CRC and high methylation level of *PAX1* was 617.8±47.5 days.

Correlation between methylation status of *PAX1*/*SOX1* and clinicopathological characteristics of CRC patients
---------------------------------------------------------------------------------------------------------------

The association of patients' demographic and clinicopathological characteristics with *PAX1*/*SOX1* methylation status was analyzed using the TCGA dataset and clinical samples. The relationship between methylation and clinicopathological characteristics in CRC is summarized in [Table S1](#SD2-ott-10-4739){ref-type="supplementary-material"} for TCGA datasets and [Table 3](#t3-ott-10-4739){ref-type="table"} for clinical samples. No significant association was found between the *PAX1* or *SOX1* methylation frequency and the clinicopathological characteristics of patients with CRC in TCGA datasets and clinical samples.

The correlation between methylation status of *PAX1*/*SOX1* in cancer tissues and clinical characteristics of CRC patients is summarized in [Table 4](#t4-ott-10-4739){ref-type="table"}. The methylated status of *SOX1* and *PAX1* was significantly associated with TNM stage. The methylation distributions in the CRC tissues from the 41 patients with CRC at various TNM stages are illustrated in [Figure 3](#f3-ott-10-4739){ref-type="fig"}. The methylation level log (meth-index) of *PAX1* in patients with CRC and high TNM stage (TNM stage III/IV) was 3.11±2.43, which was significantly higher than that of patients with low TNM stage (TNM stage I/II, 1.26±2.94, *P*\<0.05). The AUCs under ROC plots for the methylation of *SOX1* and *PAX1* to detect high TNM stage of CRC were 0.759 (95% CI 0.515--0.869) and 0.692 (95% CI 0.588--0.930), respectively. At log (meth-index) of 3.84, *PAX1* methylation testing achieved 71.4% sensitivity and 70.4% specificity. At log (meth-index) of 3.82, *PAX1* methylation testing achieved 63.0% sensitivity and 69.2% specificity.

Correlations between mRNA expression and DNA methylation of *PAX1*/*SOX1* in CRC samples
----------------------------------------------------------------------------------------

The mRNA expression level of *PAX1*/*SOX1* in the cancer and paired normal tissues of the 41 patients was quantified using quantitative RT-PCR to determine whether methylation changes in these two genes affected gene expression. The results indicated significant difference in the mRNA levels of *PAX1*/*SOX1* between CRC and paired normal tissues (*P*\<0.05, [Figure 4A and B](#f4-ott-10-4739){ref-type="fig"}). The mRNA levels of both genes were lower in the CRC samples than in their paired normal samples.

Pearson's correlation analysis was also performed to analyze the relationship between mRNA expression levels and DNA methylation ([Figure 4C and D](#f4-ott-10-4739){ref-type="fig"}). The results showed no linear relationship between methylation levels and mRNA expression of *PAX1* or *SOX1* in the same CRC sample.

Immunohistochemical expression of *PAX1*/*SOX1*
-----------------------------------------------

Immunohistochemical examination of the 41 pairs of cancer and normal tissues of patients with CRC was performed to evaluate whether methylation changes in the two genes affected protein expression. High SOX1 expression was detected in 9 (22.0%) of 41 CRC tissues and in 28 (68.2%) of 41 paracancer tissues. High SOX1 expression was detected in 9 (22.0%) of 41 CRC tissues and in 22 (53.6%) of 41 paracancer tissues. The results indicated significantly lower PAX1 and SOX1 protein expression in CRC compared with their paired normal tissues (*P*\<0.05). Typical immunohistochemical (IHC) staining images for SOX1 and PAX1 in CRC tissues and paracancer tissues are shown in [Figure 5](#f5-ott-10-4739){ref-type="fig"}.

Discussion
==========

DNA methylation is the most frequent epigenetic alteration. Hypermethylation of specific gene promoters is an important mechanism of carcinogenesis. High frequency of promoter methylation of *PAX1* and *SOX1* genes has been detected in cervical and oral cancers. In the present study, we demonstrated that the methylation levels of *PAX1* and *SOX1* are higher in colorectal tumor tissues compared with the paired normal tissues from the patients with CRC. DNA methylation at cg2,09,07,471 (*PAX1*) and cg0,66,75,478 (*SOX1*) from TCGA datasets supports our results.

*PAX1* is a member of the PAX family, which plays a key role during fetal development. The PAX gene family is classified into four groups based on the gene structure.[@b7-ott-10-4739] *PAX1* is categorized into group 1, which is the most frequently methylated gene in the *PAX* family. *PAX1* may be involved in carcinogenesis and tumor progression in invasive or aggressive carcinomas. *PAX1*, as a tumor suppressed gene, was reported to inhibit cervical, oral, and ovarian carcinomas silenced by promoter hypermethylation. A study on head and neck squamous cell carcinoma illustrated that *PAX1* participated in the Notch pathway.[@b23-ott-10-4739] *PAX1* activation was blocked by the silence of *HOX* family of transcription factors, which are downstream targets of Notch signaling.

*SOX1* is a member of the *SOX* transcription factor family, which plays crucial roles in embryonic and postnatal development and stem cell regulation.[@b24-ott-10-4739] Several members of the *SOX* family have been implicated in cancer development. *SOX10* is a novel oncogene in hepatocellular carcinoma, which could activate the Wnt/β-catenin signaling pathway.[@b25-ott-10-4739] *SOX9* is a transcription factor expressed in human fetal prostate epithelium and enhances prostate cancer invasion.[@b26-ott-10-4739] *SOX1* has been reported as a tumor suppressor to promoters in various carcinoma tissues depending on tumor status and type. *SOX1* was reported to inhibit cervical, liver, and nasopharyngeal carcinomas via the Wnt/β-catenin signaling pathway.[@b13-ott-10-4739] Moreover, *SOX1* gene could regulate prostate cancer stem cell invasion by interfering with STAT3 signaling pathway.[@b27-ott-10-4739],[@b28-ott-10-4739]

The association of *PAX1*/*SOX1* methylation to the clinicopathological characteristics of patients with CRC was analyzed to further evaluate the clinical significance of *PAX1* and *SOX1* methylation in CRC development and progression. The results showed significant association between *PAX1*/*SOX1* and TNM stage of these patients. Besides, the sensitivity and specificity of *SOX1* and *PAX1* may play important roles in the poor prognosis and tumor development in CRCs. These results were consistent with a previous study on other carcinomas. A study on hepatocellular cancer has also indicated that *SOX1* is correlated with TNM stage of hepatocellular cancer because low *SOX1* expression in cancer tissues was significantly associated with advanced TNM stage.[@b29-ott-10-4739] The methylation of *PAX1* was significantly associated with the cervical intraepithelial neoplasia (CIN) grade, and the methylation level of *PAX1* increased as the grade of CIN increased.[@b7-ott-10-4739],[@b30-ott-10-4739]

Hypermethylation was believed to play key roles in gene expression. The methylation status of *SOX1* and *PAX1* was observed to be significantly higher in cancer tissues compared with paired paracancer tissues, whereas the mRNA expression of these genes was lower in the cancer tissues. However, no evident linear relationship was found with methylation status and mRNA expression in the same sample of CRC. This phenomenon may be due to the fact that the methylation of specific CpG site in a promoter could not affect the expression of the whole gene. Nevertheless, mRNA expression of *SOX1* and *PAX1* genes was inhibited by promoter hypermethylation. This observation is in agreement with previous hepatocellular cancer studies.[@b29-ott-10-4739] In these studies, the mRNA expression of *SOX1* gene was significantly lower in hepatocellular cancer tissues than in the paired normal tissues based on the semiquantitative RT-PCR detection in 15 paired cancer tissues and paracancer tissues in hepatocellular cancer patients. In addition, mRNA expression of *SOX1* was down-regulated in nasopharyngeal cancer tissues compared with their paired paracancer tissues because of the hypermethylation of *SOX1* in nasopharyngeal cancer tissues.[@b13-ott-10-4739]

We further detected the expression of *PAX1* and *SOX1* proteins in 41 paired CRC and paracancer tissues by IHC. The expression level of *PAX1*/*SOX1* protein was significantly lower in CRC tissues than in their paired normal tissues. It can be inferred that the hypermethylation may induce the low protein expression in CRC tissues. These results were in agreement with previous studies on hepatocellular cancer.[@b29-ott-10-4739] Previous results showed that the expression level of *SOX1* protein was significantly lower in the tissues of hepatocellular cancer than in their paired normal tissues as shown by IHC and Western blot assays.

Conclusions
===========

For the first time, the hypermethylation levels of *PAX1*/*SOX1* genes in CRC are reported in this study. The methylation level of *PAX1*/*SOX1* was significantly higher in patients with CRC at high TNM stage than those at low TNM stage. Relative mRNA and protein expressions of *PAX1*/*SOX1* were downregulated by the aberrant methylation in CRC compared with their paired normal tissue. Thus, aberrant DNA methylation of *PAX1*/*SOX1* could be a potential molecular tumor biomarker for CRC screening.

Supplementary materials
=======================

###### 

Correlation between the methylation status of *SOX1* and *PAX1* in the same CRC samples.

**Notes:** Pearson's correlation was used to measure the linear relationship between methylation log (meth-index) of *PAX1* (*x*-axis) and *SOX1* (*y*-axis) in 41 CRC tissues (**A**) and 166 CRCs downloaded from TCGA dataset (**B**). *P*-values were performed by independent sample *t*-test.

**Abbreviations:** CRC, colorectal cancer; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1; TCGA, The Cancer Genome Atlas.

###### 

Association of the frequency of methylation occurrence of cg20907471 (*PAX1*) and average of cg22303211 and cg06675478 (*SOX1*) in cancer tissues to the clinical characteristics of 166 patients with CRC using TCGA datasets (n=166)

  Characteristics        N     *SOX1*   *PAX1*                                       
  ---------------------- ----- -------- ---------- ------- ------- ---- ---- ------- -------
  Age, years                                               0.239                     0.560
   Mean (SD) \[range\]   70    (11.9)   (36--90)                                     
   \<50                  15    7        8          46.67           3    12   20.00   
   50--70                61    42       19         68.85           21   40   34.43   
   \>70                  90    54       36         60.00           29   61   32.22   
  Gender                                                   0.631                     0.617
   Male                  83    53       30         63.86           28   55   33.73   
   Female                83    50       33         60.24           25   58   30.12   
  M                                                        0.576                     0.191
   M0                    142   88       54         61.97           43   99   30.28   
   M1                    24    15       9          62.50           19   14   79.17   
  N                                                        0.329                     0.209
   N0                    99    65       34         65.66           27   72   27.27   
   N1                    32    20       12         62.50           14   18   43.75   
   N2                    34    18       17         52.94           12   23   35.29   
  T                                                        0.310                     0.834
   T1                    4     1        3          25.00           2    2    50.00   
   T2                    35    24       11         68.57           10   25   28.57   
   T3                    110   69       41         62.73           36   74   32.73   
   T4                    17    9        8          52.94           5    12   29.41   
  Stage                                                    0.666                     0.646
   I                     32    22       10         68.75           9    23   28.13   
   II                    64    41       23         64.06           18   46   28.13   
   III                   45    25       20         55.56           16   29   35.56   
   IV                    24    15       10         62.50           10   15   41.67   
  CEA                                                      0.338                     0.887
   \<9.7                 78    46       32         58.97           26   52   33.33   
   \>9.7                 24    13       11         54.17           8    16   33.33   
   NA                    64    44       20         68.75           19   45   29.69   

**Note:**

Calculated *χ*^2^ test.

**Abbreviations:** CEA, carcinoembryonic antigen; CRC, colorectal cancer; M, methylated; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1; TCGA, The Cancer Genome Atlas; U, unmethylated.
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![DNA methylation of *PAX1* and *SOX1* analyzed in CRC using TCGA dataset.\
**Notes:** (**A**) Comparison of DNA methylation status of *SOX1* and *PAX1* in 166 CRC tissues and 37 normal tissues. *P*\<0.05 was considered significant. (**B**) DNA methylation status of *SOX1* and *PAX1* in 37 CRC tissues and paired normal tissues. (**C** and **D**) Kaplan--Meier estimation of overall survival according to *PAX1* and *SOX1* methylation status in 166 patients. Median methylation status of each gene was defined as cutoff. \**P*\<0.05 was calculated by independent sample *t*-test. \*\**P*\<0.05 was calculated by Wilcoxon signed-rank test. AUC data shown as value (specificity sensitivity).\
**Abbreviations:** CRC, colorectal cancer; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1; TCGA, The Cancer Genome Atlas.](ott-10-4739Fig1){#f1-ott-10-4739}

![DNA methylation status of *PAX1* and *SOX1* genes in CRC tissues and paired normal tissues from 41 patients with CRC.\
**Notes:** Comparison of DNA methylation status log (meth-index) of *PAX1* (**A**) and *SOX1* (**B**) genes in 41 CRC tissues and paired normal tissues. The AUC of the ROC curve was calculated to diagnose the CRC and normal tissues for *PAX1* (**C**) and *SOX1* (**D**). *P*-value was calculated by Wilcoxon signed-rank test.\
**Abbreviations:** AUC, areas under the curve; CRC, colorectal cancer; *PAX1*, paired boxed gene 1; ROC, receiver-operating characteristic; *SOX1*, sex-determining region Y-related high-mobility group box 1.](ott-10-4739Fig2){#f2-ott-10-4739}

![Methylation distribution of CRC tissues at various TNM stages.\
**Notes:** (**A**) Dot plots illustrate the log (meth-index) distributions of *PAX1* gene at various TNM stages. (**B**) The AUC of ROC curve was calculated to diagnose the TNM stage I/II and stage III/IV for *PAX1*. (**C**) Dot plots illustrate the log (meth-index) distributions of *SOX1* gene at various TNM stages. (**D**) The AUC of ROC curve was calculated to diagnose the TNM stage I/II and stage III/IV for *SOX1* gene. *P*\<0.05 was determined by Mann--Whitney *U*-test. Arrows show the best specificity and sensitivity.\
**Abbreviations:** AUC, areas under the curve; CRC, colorectal cancer; *PAX1*, paired boxed gene 1; ROC, receiver-operating characteristic; *SOX1*, sex-determining region Y-related high-mobility group box 1.](ott-10-4739Fig3){#f3-ott-10-4739}

###### 

mRNA expression of *SOX1*/*PAX1* genes in CRC tissues of 41 patients with CRC.

**Notes:** (**A**) Relative *SOX1* and (**B**) *PAX1* mRNA expression levels ± SEM in CRC tissues and paired normal tissues. Pearson's correlation was used to measure the linear relationship between mRNA expression (*x*-axis) and methylation level log (meth-index) (*y*-axis) of (**C**) *SOX1* and (**D**) *PAX1* genes in 41 CRC tissues. *P*-values were performed by *t*-test.

**Abbreviations:** CRC, colorectal cancer; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1.
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![Representative expression of *PAX1* and *SOX1* protein in colorectal tissues compared with paired normal tissues.\
**Notes:** (**A**) IHC staining of *SOX1* protein expression in normal tissue samples. (**B**) IHC staining of *SOX1* protein expression in CRC tissue samples. (**C**) IHC staining of *PAX1* protein expression in normal tissue samples. (**D**) IHC staining of *PAX1* protein expression in CRC tissue samples (×200).\
**Abbreviations:** CRC, colorectal cancer; IHC, immunohistochemical; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1.](ott-10-4739Fig5){#f5-ott-10-4739}

###### 

Association of the frequency of methylation occurrence of *PAX1* and *SOX1* in cancer tissues to the clinical characteristics of 41 patients with CRC

  Characteristics        N    *SOX1*    *PAX1*                                         
  ---------------------- ---- --------- ---------- -------- ------- ---- ---- -------- -------
  Age, years                                                0.460                      0.460
   Mean (SD) \[range\]   56   (12.65)   (27--84)                                       
   \<60                  25   16        9          64.00            16   9    64.00    
   \>60                  16   12        4          75.00            12   4    75.00    
  Gender                                                    0.658                      0.025
   Male                  20   13        7          65.00            17   3    85.00    
   Female                21   15        6          71.43            11   10   52.38    
  Tumor location                                            0.987                      0.987
   Colon                 19   13        6          68.42            13   6    68.42    
   Rectum                22   15        7          68.18            15   7    68.18    
  LN metastasis                                             0.203                      0.072
   N0                    29   19        10         65.52            18   11   62.07    
   N1                    11   9         2          81.82            10   1    90.91    
   N2                    1    0         1          0.00             0    1    0.00     
  Tumor invasion                                            0.548                      0.661
   T1                    3    3         0          100.00           3    0    100.00   
   T2                    12   8         4          66.67            8    4    66.67    
   T3                    5    4         1          80.00            3    2    60.00    
   T4                    21   13        8          61.90            14   7    66.67    
  TNM stage                                                 0.666                      0.646
   I                     9    7         2          77.78            7    2    77.78    
   II                    18   9         9          50.00            9    9    50.00    
   III                   12   10        2          83.33            10   2    83.33    
   IV                    2    2         0          100.00           2    0    100.00   
  Tumor HG                                                  0.432                      0.432
   Poor                  7    6         1          85.71            6    1    85.71    
   Moderate              20   12        8          60.00            12   8    60.00    
   Well                  14   10        4          71.43            10   4    71.43    
  Tumor size                                                0.063                      0.128
   \<3 cm                3    0         3          0.00             1    2    33.33    
   3--5 cm               9    6         3          66.67            4    5    44.44    
   \>5 cm                5    4         1          80.00            4    1    80.00    
   NA                    24   18        6          75.00            19   5    79.17    

**Note:**

Calculated by *χ*^2^ test.

**Abbreviations:** CRC, colorectal cancer; HG, histological grade; LN, lymph node; M, methylated; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1; U, unmethylated.

###### 

Sensitivities, specificities, and AUC of *PAX1* and *SOX1* methylation in detecting CRC tumor (n=41)

  Detection modality   Cancer   Paracancer   Sensitivity %   Specificity %   AUC    95% CI   *P*-value[\*](#tfn3-ott-10-4739){ref-type="table-fn"}                  
  -------------------- -------- ------------ --------------- --------------- ------ -------- ------------------------------------------------------- -------------- ---------
  *PAX1*               13       28           36              5               68.3   87.8     0.743                                                   0.627--0.858   \<0.001
  *SOX1*               13       28           41              0               68.3   100.0    0.798                                                   0.689--0.907   \<0.001

**Note:**

Calculated by *χ*^2^ test.

**Abbreviations:** AUC, areas under the curve; CRC, colorectal cancer; M, methylated; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1; U, unmethylated.

###### 

Sensitivities, specificities, and AUC of *PAX1* and *SOX1* methylation in detecting low (n=27) and high (n=14) TNM stages

  Detection modality   Sensitivity %   Specificity %   AUC     95% CI         *P*-value[\*](#tfn5-ott-10-4739){ref-type="table-fn"}
  -------------------- --------------- --------------- ------- -------------- -------------------------------------------------------
  *PAX1*               0.714           0.704           0.759   0.588--0.930   0.007
  *SOX1*               0.714           0.630           0.692   0.515--0.869   0.046

**Note:**

Calculated by *χ*^2^ test.

**Abbreviations:** AUC, areas under the curve; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1.

###### 

Correlation between methylation levels of *PAX1* and *SOX1* in the cancer tissues and clinical characteristics of 41 patients with CRC

  Characteristics   *PAX1* methylation level   *SOX1* methylation level               
  ----------------- -------------------------- -------------------------- ----------- -----------
  Age, years                                   0.621                                  0.779
   \<60             1.59±3.10                                             1.94±2.83   
   \>60             2.37±2.53                                             2.46±2.69   
  Gender                                       0.050                                  0.531
   Male             2.92±2.07                                             2.00±2.79   
   Female           0.92±3.24                                             2.28±2.78   
  Tumor location                               0.296                                  0.143
   Colon            2.17±2.77                                             2.33±2.66   
   Rectum           1.66±3.02                                             1.98±2.89   
  TNM stage                                    **0.007**                              **0.046**
   I/II             1.26±2.94                                             1.77±2.88   
   III/IV           3.11±2.43                                             2.87±2.43   
  Tumor size                                   0.399                                  0.792
   \<5 cm           0.19±3.37                                             1.09±3.14   
   \>5 cm           2.60±2.90                                             2.57±2.84   
  Tumor HG                                     0.273                                  0.080
   W/M              1.52±2.99                                             1.86±2.82   
   Poor             3.39±1.93                                             3.21±2.41   
  Tumor invasion                               0.665                                  0.807
   T1/2             1.92±2.85                                             2.41±2.70   
   T3/4             1.89±2.96                                             1.99±2.83   
  LN metastasis                                0.071                                  0.192
   N0               1.46±2.93                                             1.94±2.85   
   N1/2/3           2.93±2.60                                             2.65±2.56   

**Notes:**

Association analysis for methylation status by Mann--Whitney *U*-test. Significant values \<0.05 were shown in bold font.

**Abbreviations:** CRC, colorectal carcinoma; LN, lymph node; HG, histological grade; *PAX1*, paired boxed gene 1; *SOX1*, sex-determining region Y-related high-mobility group box 1; W/M, well/moderate.
